Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency | Zendy

Bradley S. Dixon | Zendy; Gerald J. Beck | Zendy; Miguel A. Vázquez | Zendy; Arthur Greenberg | Zendy; James A. Delmez | Zendy; Michael Allon | Zendy; Laura M. Dember | Zendy; Jonathan Himmelfarb | Zendy; Jennifer Gassman | Zendy; Tom Greene | Zendy; Milena Radeva | Zendy; Ingemar Davidson | Zendy; T. Alp İkizler | Zendy; Gregory L. Braden | Zendy; Andrew Z. Fenves | Zendy; James S. Kaufman | Zendy; James R. Cotton | Zendy; Kévin Martin | Zendy; James W. McNeil | Zendy; A. Rahman | Zendy; Jeffery H. Lawson | Zendy; James F. Whiting | Zendy; Bo Hu | Zendy; Catherine M. Meyers | Zendy; John W. Kusek | Zendy; Harold I. Feldman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency

Author(s) -

Bradley S. Dixon,

Gerald J. Beck,

Miguel A. Vázquez,

Arthur Greenberg,

James A. Delmez,

Michael Allon,

Laura M. Dember,

Jonathan Himmelfarb,

Jennifer Gassman,

Tom Greene,

Milena Radeva,

Ingemar Davidson,

T. Alp İkizler,

Gregory L. Braden,

Andrew Z. Fenves,

James S. Kaufman,

James R. Cotton,

Kévin Martin,

James W. McNeil,

A. Rahman,

Jeffery H. Lawson,

James F. Whiting,

Bo Hu,

Catherine M. Meyers,

John W. Kusek,

Harold I. Feldman

Publication year - 2009

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0805840

Subject(s) - medicine , dipyridamole , aspirin , hemodialysis , placebo , hazard ratio , thrombosis , surgery , cumulative incidence , adverse effect , randomized controlled trial , anesthesia , confidence interval , transplantation , alternative medicine , pathology

Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research